Judith A Anesi1,2,3, Emily A Blumberg1, Jennifer H Han4, Dong Heun Lee5, Heather Clauss6, Richard Hasz7, Esther Molnar6, Darcy Alimenti2, Andrew R Motzer6, Sharon West7, Warren B Bilker2,3, Pam Tolomeo2,3, Ebbing Lautenbach1,2,3. 1. Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 2. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 3. Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 4. GlaxoSmithKline, Rockville, Maryland, USA. 5. Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, USA. 6. Section of Infectious Diseases, Department of Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA. 7. Gift of Life Donor Program, Philadelphia, Pennsylvania, USA.
Abstract
BACKGROUND: The impact of donor colonization or infection with multidrug-resistant organisms (MDROs) on solid organ transplant (SOT) recipient outcomes remains uncertain. We thus evaluated the association between donor MDROs and risk of posttransplant infection, graft failure, and mortality. METHODS: A multicenter retrospective cohort study was performed. All SOT recipients with a local deceased donor were included. The cohort was divided into three exposure groups: recipients whose donors had (1) an MDRO, (2) a non-MDRO bacterial or candidal organism, or (3) no growth on cultures. The primary outcomes were (1) bacterial or invasive candidal infection within 3 months and (2) graft failure or death within 12 months posttransplant. Mixed effect multivariable frailty models were developed to evaluate each association. RESULTS: Of 658 total SOT recipients, 93 (14%) had a donor with an MDRO, 477 (73%) had a donor with a non-MDRO organism, and 88 (13%) had a donor with no organisms on culture. On multivariable analyses, donor MDROs were associated with a significantly increased hazard of infection compared to those with negative donor cultures (adjust hazard ratio [aHR] 1.63, 95% CI 1.01-2.62, p = .04) but were not associated with graft failure or death (aHR 0.45, 95% CI 0.15-1.36, p = .16). CONCLUSIONS: MDROs on donor culture increase the risk of early posttransplant infection but do not appear to affect long-term graft or recipient survival, suggesting organ donors with MDROs on culture may be safely utilized. Future studies aimed at reducing early posttransplant infections associated with donor MDROs are needed.
BACKGROUND: The impact of donor colonization or infection with multidrug-resistant organisms (MDROs) on solid organ transplant (SOT) recipient outcomes remains uncertain. We thus evaluated the association between donor MDROs and risk of posttransplant infection, graft failure, and mortality. METHODS: A multicenter retrospective cohort study was performed. All SOT recipients with a local deceased donor were included. The cohort was divided into three exposure groups: recipients whose donors had (1) an MDRO, (2) a non-MDRO bacterial or candidal organism, or (3) no growth on cultures. The primary outcomes were (1) bacterial or invasive candidal infection within 3 months and (2) graft failure or death within 12 months posttransplant. Mixed effect multivariable frailty models were developed to evaluate each association. RESULTS: Of 658 total SOT recipients, 93 (14%) had a donor with an MDRO, 477 (73%) had a donor with a non-MDRO organism, and 88 (13%) had a donor with no organisms on culture. On multivariable analyses, donor MDROs were associated with a significantly increased hazard of infection compared to those with negative donor cultures (adjust hazard ratio [aHR] 1.63, 95% CI 1.01-2.62, p = .04) but were not associated with graft failure or death (aHR 0.45, 95% CI 0.15-1.36, p = .16). CONCLUSIONS: MDROs on donor culture increase the risk of early posttransplant infection but do not appear to affect long-term graft or recipient survival, suggesting organ donors with MDROs on culture may be safely utilized. Future studies aimed at reducing early posttransplant infections associated with donor MDROs are needed.
Authors: Katherine G Phillips; Neel K Ranganath; Jad Malas; Bonnie E Lonze; Claudia G Gidea; Deane E Smith; Zachary N Kon; Alex Reyentovich; Nader Moazami Journal: Ann Thorac Surg Date: 2019-06-06 Impact factor: 4.330
Authors: J M Wendt; D Kaul; B M Limbago; M Ramesh; S Cohle; A M Denison; E M Driebe; J K Rasheed; S R Zaki; D M Blau; C D Paddock; L K McDougal; D M Engelthaler; P S Keim; C C Roe; H Akselrod; M J Kuehnert; S V Basavaraju Journal: Am J Transplant Date: 2014-09-22 Impact factor: 8.086
Authors: Daniel R Kaul; Gabe Vece; Emily Blumberg; Ricardo M La Hoz; Michael G Ison; Michael Green; Timothy Pruett; Michael A Nalesnik; Susan M Tlusty; Amber R Wilk; Cameron R Wolfe; Marian G Michaels Journal: Am J Transplant Date: 2020-07-25 Impact factor: 8.086
Authors: A Mularoni; A Bertani; G Vizzini; F Gona; M Campanella; M Spada; S Gruttadauria; P Vitulo; P Conaldi; A Luca; B Gridelli; P Grossi Journal: Am J Transplant Date: 2015-05-15 Impact factor: 8.086
Authors: S Jolivet; I Lolom; S Bailly; L Bouadma; B Lortat-Jacob; P Montravers; L Armand-Lefevre; J-F Timsit; J-C Lucet Journal: J Hosp Infect Date: 2020-02-22 Impact factor: 3.926
Authors: Ali Bashir; Oliver Attie; Mitchell Sullivan; Robert Sebra; Kavindra V Singh; Deena Altman; Theodore Pak; Jayeeta Dutta; Kieran Chacko; Elizabeth Webster; Martha Lewis; Camille Hamula; Kristin W Delli Carpini; Barbara E Murray; Andrew Kasarskis; Harm van Bakel; Shirish Huprikar Journal: PLoS One Date: 2017-03-16 Impact factor: 3.240
Authors: Elena Pérez-Nadales; Mario Fernández-Ruiz; Belén Gutiérrez-Gutiérrez; Álvaro Pascual; Jesús Rodríguez-Baño; Luis Martínez-Martínez; José María Aguado; Julian Torre-Cisneros Journal: Transpl Infect Dis Date: 2022-06-28